RPTR 147 1
Alternative Names: RPTR-147-1Latest Information Update: 28 Jun 2024
Price :
$50 *
At a glance
- Originator Repertoire Immune Medicines
- Class Antineoplastics; Gene therapies; Immunotherapies; Interleukins; T lymphocyte cell therapies
- Mechanism of Action Alpha-galactosidase A transport modulators; Immunologic cytotoxicity; Interleukin 15 replacements; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Malignant melanoma; Solid tumours
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for phase-I development in Malignant-melanoma(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (Parenteral)
- 28 Jun 2024 No recent reports of development identified for phase-I development in Malignant-melanoma(Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in USA (Parenteral)
- 28 Jun 2024 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (Parenteral)